Legend Biotech (LEGN) Q2 2026 Earnings Call Transcript

Legend Biotech reported Q2 2026 adjusted net income of $63.1M (=$0.16/share) versus $10.1M in Q2 2025, driven by 52% YoY revenue growth to $387.5M and operating margin improving to 15% from negative 9% a year earlier. CARVYKTI worldwide net trade sales rose 50% YoY to ~$657M, with U.S. sales up 32% YoY to ~$472M and ex-U.S. up 128% YoY to ~$185M, while cash increased to ~$965M after a June $212M net equity raise. Management guided Q3 gross margin on net product sales to the lower-50% range (from 58% in Q2) with a rebound to the mid-50% range in Q4, and reiterated momentum toward an IND filing for LB2501 in Q4 2026.

Analysis

LEGN’s setup is improving, but the market should separate commercial durability from accounting noise. The real signal is earlier-line penetration plus outpatient conversion: that increases lifetime value per patient, expands site throughput, and should eventually lift gross margin even if near-term mix makes quarter-to-quarter margins lumpy. JNJ is the main economic partner, but the more interesting second-order effect is on bispecifics and other continuous-therapy regimens: if CAR-T becomes the preferred "sequence first" choice, later-line competitors can still win share, but they lose the highest-value patients and the narrative shifts from class expansion to selection of timing.

The near-term risk is that investors over-extrapolate Q2 profitability into a straight line. Q3 margin guidance in the low-50s means the stock can sell off on any miss even if the business is healthy; the market tends to punish biotech when margin inflections look transitory. The bigger 1-3 month catalyst is whether management can show durable 2L/3L mix expansion without sacrificing throughput, and whether the year-end IND for LB2501 is executed cleanly. Over 6-18 months, the key structural test is whether the company can convert today’s commercial momentum into credible frontline data and a real in vivo platform, rather than a single-asset story.

Contrarian view: consensus may be underestimating how much of the upside is already in the stock from the CARVYKTI commercial ramp, while overestimating how easy it is to repeat this with new modalities. The market is likely to reward the profitability milestone, but the multiple can compress if leadership uncertainty, tax rate normalization, or a softer Q3 margin print makes the earnings quality look less scalable than the headline suggests. The thesis is falsified if Q3 gross margin stays below the low-50s, second-half profitability is delayed, or the 6-month durability data for LB2501/LB2505 fails to validate the platform story.

Key Decisions for Investors

• Go long LEGN on any post-earnings weakness that is driven by the Q3 margin guide rather than demand: 3-6 month horizon, targeting rerating if management reaffirms second-half profitability and year-end IND filing. Risk/reward is favorable as long as gross margin does not deteriorate below ~52% on a sustained basis.
• Use a LEGN call spread into the next catalyst window (Q4 IND filing / conference updates) instead of outright common if you want convexity: the stock can re-rate on platform optionality, but implied execution risk around leadership transition and margin normalization argues for defined risk.
• If hedging biotech beta, pair long LEGN with short XBI for 1-3 months: the idiosyncratic cash flow improvement and platform upside should outperform a beta basket if CARVYKTI data hold, while XBI absorbs sector-wide disappointment risk.
• Avoid chasing JNJ as the cleaner long on this print: it captures only a fraction of the economics, while LEGN has the stronger operating leverage and higher sensitivity to CARVYKTI sequencing gains. The trade works only if the market keeps rewarding earlier-line share gains.
• Set a watch item on Q3 gross margin and 2H26 adjusted net income guidance; if either slips materially, fade the move. That would be the first sign that mix/outpatient dynamics are creating more margin drag than the market currently assumes.